Effective pharmacotherapy of alcoholic amnestic disorder with fluvoxamine. Preliminary findings

P. R. Martin, B. Adinoff, M. J. Eckardt, J. M. Stapleton, G. A H Bone, D. R. Rubinow, E. A. Lane, M. Linnoila

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Ten patients with alcoholic chronic organic brain disease were categorized as having alcohol amnestic disorder, or Korsakoff's psychosis (n=6), dementia associated with alcoholism (n=3), or compensated alcoholic liver disease (n=1). All patients had severe deficits in memory for recently acquired information (episodic memory). Patients with alcohol dementia also showed global intellectual decline, including decreased performance on measures of semantic (knowledge) memory and reduction in levels of cerebrospinal fluid somatostatin. In a 4-week double-blind crossover design, the serotonin-uptake blocker fluvoxamine maleate (100 to 200 mg/d) was found to improve episodic memory in only the patients with alcohol amnestic disorder. These improvements in memory were significantly correlated with reductions in levels of cerebrospinal fluid 5-hydroxyindoleacetic acid, suggesting that facilitation of serotonergic neurotransmission may ameliorate the episodic memory failure in patients with alcohol amnestic disorder.

Original languageEnglish (US)
Pages (from-to)617-621
Number of pages5
JournalArchives of General Psychiatry
Volume46
Issue number7
StatePublished - 1989

Fingerprint

Fluvoxamine
Alcohol Amnestic Disorder
Episodic Memory
Drug Therapy
Cerebrospinal Fluid
Dementia
Korsakoff Syndrome
Alcoholic Liver Diseases
Hydroxyindoleacetic Acid
Memory Disorders
Brain Diseases
Somatostatin
Semantics
Synaptic Transmission
Cross-Over Studies
Alcoholism
Serotonin
Alcohols

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Martin, P. R., Adinoff, B., Eckardt, M. J., Stapleton, J. M., Bone, G. A. H., Rubinow, D. R., ... Linnoila, M. (1989). Effective pharmacotherapy of alcoholic amnestic disorder with fluvoxamine. Preliminary findings. Archives of General Psychiatry, 46(7), 617-621.

Effective pharmacotherapy of alcoholic amnestic disorder with fluvoxamine. Preliminary findings. / Martin, P. R.; Adinoff, B.; Eckardt, M. J.; Stapleton, J. M.; Bone, G. A H; Rubinow, D. R.; Lane, E. A.; Linnoila, M.

In: Archives of General Psychiatry, Vol. 46, No. 7, 1989, p. 617-621.

Research output: Contribution to journalArticle

Martin, PR, Adinoff, B, Eckardt, MJ, Stapleton, JM, Bone, GAH, Rubinow, DR, Lane, EA & Linnoila, M 1989, 'Effective pharmacotherapy of alcoholic amnestic disorder with fluvoxamine. Preliminary findings', Archives of General Psychiatry, vol. 46, no. 7, pp. 617-621.
Martin, P. R. ; Adinoff, B. ; Eckardt, M. J. ; Stapleton, J. M. ; Bone, G. A H ; Rubinow, D. R. ; Lane, E. A. ; Linnoila, M. / Effective pharmacotherapy of alcoholic amnestic disorder with fluvoxamine. Preliminary findings. In: Archives of General Psychiatry. 1989 ; Vol. 46, No. 7. pp. 617-621.
@article{9c0705ff3824454dbf569525d06b7f85,
title = "Effective pharmacotherapy of alcoholic amnestic disorder with fluvoxamine. Preliminary findings",
abstract = "Ten patients with alcoholic chronic organic brain disease were categorized as having alcohol amnestic disorder, or Korsakoff's psychosis (n=6), dementia associated with alcoholism (n=3), or compensated alcoholic liver disease (n=1). All patients had severe deficits in memory for recently acquired information (episodic memory). Patients with alcohol dementia also showed global intellectual decline, including decreased performance on measures of semantic (knowledge) memory and reduction in levels of cerebrospinal fluid somatostatin. In a 4-week double-blind crossover design, the serotonin-uptake blocker fluvoxamine maleate (100 to 200 mg/d) was found to improve episodic memory in only the patients with alcohol amnestic disorder. These improvements in memory were significantly correlated with reductions in levels of cerebrospinal fluid 5-hydroxyindoleacetic acid, suggesting that facilitation of serotonergic neurotransmission may ameliorate the episodic memory failure in patients with alcohol amnestic disorder.",
author = "Martin, {P. R.} and B. Adinoff and Eckardt, {M. J.} and Stapleton, {J. M.} and Bone, {G. A H} and Rubinow, {D. R.} and Lane, {E. A.} and M. Linnoila",
year = "1989",
language = "English (US)",
volume = "46",
pages = "617--621",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "7",

}

TY - JOUR

T1 - Effective pharmacotherapy of alcoholic amnestic disorder with fluvoxamine. Preliminary findings

AU - Martin, P. R.

AU - Adinoff, B.

AU - Eckardt, M. J.

AU - Stapleton, J. M.

AU - Bone, G. A H

AU - Rubinow, D. R.

AU - Lane, E. A.

AU - Linnoila, M.

PY - 1989

Y1 - 1989

N2 - Ten patients with alcoholic chronic organic brain disease were categorized as having alcohol amnestic disorder, or Korsakoff's psychosis (n=6), dementia associated with alcoholism (n=3), or compensated alcoholic liver disease (n=1). All patients had severe deficits in memory for recently acquired information (episodic memory). Patients with alcohol dementia also showed global intellectual decline, including decreased performance on measures of semantic (knowledge) memory and reduction in levels of cerebrospinal fluid somatostatin. In a 4-week double-blind crossover design, the serotonin-uptake blocker fluvoxamine maleate (100 to 200 mg/d) was found to improve episodic memory in only the patients with alcohol amnestic disorder. These improvements in memory were significantly correlated with reductions in levels of cerebrospinal fluid 5-hydroxyindoleacetic acid, suggesting that facilitation of serotonergic neurotransmission may ameliorate the episodic memory failure in patients with alcohol amnestic disorder.

AB - Ten patients with alcoholic chronic organic brain disease were categorized as having alcohol amnestic disorder, or Korsakoff's psychosis (n=6), dementia associated with alcoholism (n=3), or compensated alcoholic liver disease (n=1). All patients had severe deficits in memory for recently acquired information (episodic memory). Patients with alcohol dementia also showed global intellectual decline, including decreased performance on measures of semantic (knowledge) memory and reduction in levels of cerebrospinal fluid somatostatin. In a 4-week double-blind crossover design, the serotonin-uptake blocker fluvoxamine maleate (100 to 200 mg/d) was found to improve episodic memory in only the patients with alcohol amnestic disorder. These improvements in memory were significantly correlated with reductions in levels of cerebrospinal fluid 5-hydroxyindoleacetic acid, suggesting that facilitation of serotonergic neurotransmission may ameliorate the episodic memory failure in patients with alcohol amnestic disorder.

UR - http://www.scopus.com/inward/record.url?scp=0024340348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024340348&partnerID=8YFLogxK

M3 - Article

C2 - 2472126

AN - SCOPUS:0024340348

VL - 46

SP - 617

EP - 621

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 7

ER -